NEW YORK (GenomeWeb) – Sygnis said it has greatly expanded its Asian distribution network with a trio of deals with PhileKorea, Pharma Tech Korea, and Axil Scientific covering South Korea and Singapore.
Sygnis has granted non-exclusive rights to promote, market, and sell all existing and future product lines. PhileKorea and Pharma Tech Korea's deals cover the South Korean market; Axil Scientific's deal is for the Singaporean market.
Financial and other terms of the agreements were not disclosed.
The deals allow the firm to "significantly expand our footprint in the Asian markets," Sygnis CEO and CFO Pilar de la Huerta said in a statement. "We are very focused and committed to further building up and expanding our distribution channel program in 2016 in order to make our products widely available."
Sygnis has closed deals with a number of distributors around the world. Most recently, in August, it signed distribution agreements with GeneWorks for Australia and Nanodigmbio for China.